RAPT and GSK Related Headlines
Go Back- Wells Fargo Downgrades Rapt Therapeutics (RAPT) to Equal Weight
- Guggenheim Downgrades Rapt Therapeutics (RAPT) to Neutral
- Clear Street Downgrades Rapt Therapeutics (RAPT) to Hold
- GSK to acquire RAPT Therapeutics for $2.2 billion in food allergy deal

